A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

October 7, 2021

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions

Carcinoma, Renal CellCarcinoma Colon

Interventions

DRUG

bexmarilimab

A single neoadjuvant dose will be administered prior to surgery.

Trial Locations (1)

Turku University Hospital, Turku